Consolidative use of radiotherapy to block oligoprogression in patients with metastatic melanoma on Systemic Therapy (CURB-Melanoma) - a single arm, phase 2 clinical trial - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Evaluating Radiotherapy as a Consolidative Approach to Manage Oligoprogression in Metastatic Melanoma Patients Undergoing Systemic Treatment (CURB-Melanoma) - A Phase 2 Single-Arm Clinical Trial

  • By

  • Oded Icht

  • Alexander Sun

  • Philip Wong

  • Andrew McPartlin

  • Thiago Pimentel Muniz

  • Anna Spreafico

  • Samuel D. Saibil

  • J. Nicholas Lukens

  • Sana D Karam

  • John De Almeida

  • Marcus O. Butler

  • C. Jillian Tsai

  • July 6, 2026

Share

Clinical Scorecard: Evaluating Radiotherapy as a Consolidative Approach to Manage Oligoprogression in Metastatic Melanoma Patients Undergoing Systemic Treatment (CURB-Melanoma) - A Phase 2 Single-Arm Clinical Trial

At a Glance

CategoryDetail
ConditionOligoprogression in Metastatic Melanoma
Key MechanismsStereotactic body radiation therapy (SBRT) or hypofractionated radiation to oligoprogressive sites
Target PopulationPatients with metastatic melanoma on first-line systemic therapy with ≤10 extracranial oligoprogressive sites
Care SettingPhase 2 clinical trial at Princess Margaret Cancer Centre, Toronto, Canada

Key Highlights

  • Primary endpoint is progression-free survival (PFS) from enrollment to further disease progression.
  • Secondary endpoints include overall survival, time on current systemic therapy, and quality of life assessments.
  • Trial aims to enroll 52 patients over 12 months with 24 months of follow-up.

Guideline-Based Recommendations

Diagnosis

  • Oligoprogression defined using modified RECIST 1.1 or PERCIST criteria.

Management

  • Incorporate SBRT or hypofractionated radiotherapy while continuing systemic therapy.

Monitoring & Follow-up

  • Assess treatment-related adverse events using CTCAE v5.0.

Risks

  • Potential treatment-related adverse events and progression of disease.

Patient & Prescribing Data

Adults (age ≥18) with metastatic melanoma exhibiting oligoprogression.

Patients will remain on current systemic therapy while receiving SBRT.

Clinical Best Practices

  • Utilize validated instruments for quality of life evaluations.
  • Collect serial blood samples for exploratory analyses of circulating tumor DNA and immune profiling.

Related Resources & Content

Original Source(s)

Consolidative use of radiotherapy to block oligoprogression in patients with metastatic melanoma on Systemic Therapy (CURB-Melanoma) - a single arm, phase 2 clinical trial

  • by Oded Icht, Alexander Sun, Philip Wong, Andrew McPartlin, Thiago Pimentel Muniz, Anna Spreafico, Samuel D. Saibil, J. Nicholas Lukens, Sana D Karam, John De Almeida, Marcus O. Butler, C. Jillian Tsai

  • July 6, 2026

Related Content

Innovative pathological and therapeutic approaches for poorly cohesive gastric cancer

A pretreatment multiphasic CT-based decision-support model for differentiating pediatric hepatoblastoma from focal nodular hyperplasia

Editorial: Multi-omics interrogation of tumor-associated macrophages: paving the way for next-generation cancer immunotherapies